Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Seres Therapeutics (MCRB) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $56.4 million.

  • Seres Therapeutics' Accumulated Depreciation & Amortization rose 805.6% to $56.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.4 million, marking a year-over-year increase of 805.6%. This contributed to the annual value of $53.2 million for FY2024, which is 839.07% up from last year.
  • As of Q3 2025, Seres Therapeutics' Accumulated Depreciation & Amortization stood at $56.4 million, which was up 805.6% from $55.3 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Accumulated Depreciation & Amortization peaked at $56.4 million during Q3 2025, and registered a low of $35.8 million during Q1 2021.
  • Over the past 5 years, Seres Therapeutics' median Accumulated Depreciation & Amortization value was $48.0 million (recorded in 2023), while the average stood at $47.3 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 2116.5% in 2021, then skyrocketed by 281.51% in 2025.
  • Quarter analysis of 5 years shows Seres Therapeutics' Accumulated Depreciation & Amortization stood at $40.3 million in 2021, then rose by 11.85% to $45.0 million in 2022, then increased by 8.97% to $49.1 million in 2023, then grew by 8.39% to $53.2 million in 2024, then rose by 5.98% to $56.4 million in 2025.
  • Its last three reported values are $56.4 million in Q3 2025, $55.3 million for Q2 2025, and $54.3 million during Q1 2025.